1. Home
  2. KNSA vs PBI Comparison

KNSA vs PBI Comparison

Compare KNSA & PBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • PBI
  • Stock Information
  • Founded
  • KNSA 2015
  • PBI 1920
  • Country
  • KNSA United Kingdom
  • PBI United States
  • Employees
  • KNSA N/A
  • PBI N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • PBI Office Equipment/Supplies/Services
  • Sector
  • KNSA Health Care
  • PBI Miscellaneous
  • Exchange
  • KNSA Nasdaq
  • PBI Nasdaq
  • Market Cap
  • KNSA 1.5B
  • PBI 1.5B
  • IPO Year
  • KNSA 2018
  • PBI N/A
  • Fundamental
  • Price
  • KNSA $20.21
  • PBI $8.02
  • Analyst Decision
  • KNSA Strong Buy
  • PBI
  • Analyst Count
  • KNSA 6
  • PBI 0
  • Target Price
  • KNSA $37.17
  • PBI N/A
  • AVG Volume (30 Days)
  • KNSA 638.0K
  • PBI 2.3M
  • Earning Date
  • KNSA 04-29-2025
  • PBI 05-01-2025
  • Dividend Yield
  • KNSA N/A
  • PBI 3.00%
  • EPS Growth
  • KNSA N/A
  • PBI N/A
  • EPS
  • KNSA N/A
  • PBI N/A
  • Revenue
  • KNSA $423,239,000.00
  • PBI $2,026,598,000.00
  • Revenue This Year
  • KNSA $37.21
  • PBI N/A
  • Revenue Next Year
  • KNSA $2.58
  • PBI $0.45
  • P/E Ratio
  • KNSA N/A
  • PBI $14.32
  • Revenue Growth
  • KNSA 56.60
  • PBI N/A
  • 52 Week Low
  • KNSA $16.56
  • PBI $3.92
  • 52 Week High
  • KNSA $28.15
  • PBI $11.01
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 44.56
  • PBI 36.69
  • Support Level
  • KNSA $18.26
  • PBI $7.74
  • Resistance Level
  • KNSA $21.24
  • PBI $8.68
  • Average True Range (ATR)
  • KNSA 1.12
  • PBI 0.45
  • MACD
  • KNSA -0.12
  • PBI -0.03
  • Stochastic Oscillator
  • KNSA 44.43
  • PBI 33.51

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About PBI Pitney Bowes Inc.

Pitney Bowes Inc is a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the globe. The company's reportable segments are SendTech Solutions and Presort Services. SendTech Solutions includes the revenue and related expenses from physical and digital mailing and shipping technology solutions, financing, services, supplies and other applications to help simplify and save on the sending, tracking and receiving of letters, parcels and flats. Presort Services includes the revenue and related expenses from sortation services to qualify large volumes of First Class Mail, Marketing Mail and Marketing Mail Flats/Bound Printed Matter for postal worksharing discounts. It derives maximum revenue from SendTech Solutions.

Share on Social Networks: